Key result
LVAD implantation is linked to high infection rates, with MCS-specific infections in ~54% of patients.
Why the study?
Although left ventricular assist devices improve survival and quality of life in end-stage heart failure, infectious complications are common and significantly impact patient follow-up and mortality. This study aimed to investigate the clinical outcomes, epidemiology, risk factors, severity indicators, and mortality impact of these infections.
What are the clinical outcomes, epidemiology, risk factors, severity indicators, and impact on mortality of infectious complications in patients with end-stage heart failure undergoing left ventricular assist device (LVAD) implantation?
Cohort (n=93)
No
What are the clinical outcomes, epidemiology, risk factors, severity indicators, and impact on mortality of infectious complications in patients with end-stage heart failure undergoing left ventricular assist device (LVAD) implantation?
Infectious complications occur in over half of LVAD recipients, with non-MCS-specific infections driving early one-year mortality and MCS-specific infections impacting late survival.
Answers are grounded in this paper and cite their sources.
Infections drive LVAD morbidity; retrospective data leave open prospective validation of risk factors before guiding practice.
Introduction Left ventricular assist devices (LVAD), a durable mechanical circulatory support (MCS), have improved survival and quality of life in patients with end-stage heart failure. Nevertheless, infectious complications are common and have a significant impact on the follow-up and mortality of these patients. This single-centre retrospective study investigates the clinical outcomes, epidemiology, risk factors, severity indicators, and impact on mortality of these infections. Methodology We collected data from 93 patients who underwent LVAD implantation between January 2014 and March 2024 at the Timone University Hospital, Marseille, France. Infections were defined according to the International Society for Heart and Lung Transplantation criteria. Results In our cohort, we identified 50 patients with MCS-specific infections (53.8%). Forty-five of them had a percutaneous lead infection (90.0%) and 10 had infection of the external surface of an implantable component (20.0%). We also registered 56 patients with at least one non-MCS-specific infection (60.2%). Percutaneous lead infections, complicated or not, occurred at a late stage (after more than three months) in the majority of cases, and were associated with Staphylococcus aureus in over half of all cases. In bivariate analysis, the severity factors for a MCS-specific infection were age and high white blood cell count. During our follow-up period, 37 patients died (40.2%). Non-MCS-specific infections appear to be related with lower one-year survival, whereas MCS-specific infections could affect long-term follow-up survival. Conclusion Infectious complications after LVAD implantation are frequent and difficult to treat. Non-MCS-specific infections are correlated with early mortality, whereas MCS-specific infections impact late survival.
No takes yet. Share an insight, caveat, or question.
Vincent et al. (2026) conducted a cohort in End-stage heart failure treated with left ventricular assist devices (LVAD) (n=93). LVAD-associated infections (MCS-specific and non-MCS-specific infections) vs. Uninfected LVAD patients or infection subtypes was evaluated on MCS-specific infections, non-MCS-specific infections, and all-cause mortality. LVAD implantation was associated with MCS-specific infections in 53.8% of patients, non-MCS-specific infections in 60.2%, and a 40.2% overall mortality rate.
Synapse has enriched 10 related papers. Consider them for comparative context: